Abstract
To observe the efficacy of Anti-VEGF therapy for different patterns of optical coherence tomography of diabetic macular edema, and to explore the relationship between the integrity of the ellipsoid zone (EZ) and visual acuity outcomes. A total of 90 affected eyes with DME who received anti-VEGF therapy were enrolled in this study. The examination of BCVA was according to Early Treatment Diabetic Retinopathy Study, and the results were recorded as logarithm of the minimum angle of resolution (logMAR). Spectral-domain OCT was used to measure central macular thickness (CMT) and assess the integrity of the ellipsoid zone.All eyes were classified into three groups based on OCT patterns: diffuse retinal thickening (DRT group, 29 eyes), cystoid macular edema (CME group, 30 eyes), and serous retinal detachment (SRD group, 31 eyes). All patients received an intravitreal injection of 0.05 ml (2.5 mg) conbercept.Changes in BCVA and CMT among the three groups were compared and analyzed at baseline and at 3, 6, and 12 months after treatment. The length of the EZ defect was measured. Based on the extent of EZ disruption, eyes were classified into three grades (0, 1, and 2) to analyze the correlation between EZ integrity and visual acuity. In addition, factors influencing post-treatment visual acuity were analyzed. Compared with the central macular thickness (CMT) before treatment, the CMT of the affected eyes was significantly decreased in the diabetic retinal thickening (DRT) group (t = 6.506, 4.134, 7.782, P < 0.05), cystoid macular edema (CME) group (t = 15.407, 20.746, 24.749, P < 0.05) and serous retinal detachment (SRD) group (t = 9.580, 14.823, 16.931, P < 0.05), with statistically significant differences. Compared with the baseline, the best-corrected visual acuity (BCVA) of the affected eyes was significantly improved at 3, 6 and 12 months after treatment in the DRT group (t = 8.667, 17.050, 9.114, P < 0.05), CME group (t = 12.104, 11.583, 9.204, P < 0.05) and SRD group (t = 7.726, 9.310, 11.757, P < 0.05), with statistically significant differences. There were statistically significant differences in the LogMAR BCVA among the DRT, CME and SRD groups before treatment and at each time point after treatment (F = 11.379, 11.461, 15.282, 7.782, P < 0.05). A statistically significant difference was observed in the ellipsoid zone grading among the DRT, CME and SRD groups (χ²=21.179, P < 0.005). Compared with the baseline, the visual acuity was significantly improved at 3, 6 and 12 months after treatment in patients with ellipsoid zone grade 0 (t = 10.178, 12.375, 8.881, P < 0.05), grade 1 (t = 12.353, 13.914, 12.175, P < 0.05) and grade 2 (t = 5.154, 8.192, 8.712, P < 0.05) of LogMAR BCVA ellipsoid zone grading, respectively. Among the three ellipsoid zone groups, patients with ellipsoid zone grade 0 had the best visual acuity, while those with grade 2 had the worst visual acuity; statistically significant differences were found among the three groups before treatment and at 3, 6 and 12 months after treatment. The visual acuity at 12 months after treatment was significantly correlated with diabetic macular edema (DME) classification, ellipsoid zone defect grading, BCVA before treatment and CMT before treatment (r = 0.372, 0.547, 0.745, 0.309, all P < 0.05), while no significant correlations were found with age, duration of diabetes, glycosylated hemoglobin A1c (HbA1c), diabetic retinopathy (DR) stage and CMT at 12 months after treatment (r=-0.103, -0.035, 0.173, -0.026, 0.084, all P > 0.05). Anti-VEGF therapy could significantly improve the visual acuity of different patterns of DME, reduced the CMT, and had the best efficacy in the DRT group. There was relationship between the integrity of ellipsoid zone and the visual acuity outcomes.
Data availability
All data supporting the conclusions of this study are included as additional files in the supplementary information associated with this article and are available upon request from the corresponding author.
References
Yau, J. W. et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 35, 556–564 (2012).
Kim, E. J. et al. Treatment of diabetic macular edema. Curr. Diab Rep. 19, 68 (2019). https://pubmed.ncbi.nlm.nih.gov/31359157/
Cohen, S. R. & Gardner, T. W. Diabetic retinopathy and diabetic macular edema. Dev. Ophthalmol. 55, 137–146 (2016).
Browning, D. J., Stewart, M. W. & Lee, C. Diabetic macular edema: evidence-based management. Indian J. Ophthalmol. 66, 1736–1750 (2018).
Coscas, G., Cunha-Vaz, J. & Soubrane, G. Macular edema: definition and basic concepts. Dev. Ophthalmol. 58, 1–10 (2017).
Cetin, E. N. et al. Quantitative assessment of macular contraction and vitreoretinal interface alterations in diabetic macular edema treated with intravitreal anti-VEGF injections. Graefes Arch. Clin. Exp. Ophthalmol. 256, 1801–1806 (2018).
Hussain, R. M. & Ciulla, T. A. Treatment strategies for refractory diabetic macular edema: switching anti-VEGF treatments, adopting corticosteroid-based treatments, and combination therapy. Expert Opin. Biol. Ther. 16, 365–374 (2016).
Shimura, M. et al. Visual outcome after intravitreal bevacizumab depends on the optical coherence tomographic patterns of patients with diffuse diabetic macular edema. Retina 33, 740–747 (2012).
Fu, Y. D. et al. Efficacy of intravitreal injection of ranibizumab for different patterns of optical coherence tomography of diabetic macular edema and the relationship between integrity of ellipsoidal zone and visual acuity outcomes. Chin. J. Ocul Fundus Dis. 33, 129–133 (2017).
Vujosevic, S. et al. Imaging retinal inflammatory biomarkers after intravitreal steroid and anti-VEGF treatment in diabetic macular oedema. Acta Ophthalmol. 95, 464–471 (2017).
Subramanian, M. L. et al. Preoperative visual acuity as a prognostic indication for laser treatment of macular edema due to branch retinal vein occlusion. Ophthalmic Surg. Laser Imaging. 37, 462–467 (2006).
Hirami, Y. et al. Association of clinical characteristics with disease subtypes, initial visual acuity, and visual prognosis in neovascular age-related macular degeneration. Jpn. J. Ophthalmol. 53, 396–407 (2009).
Kwon, S. I., Ko, S. J. & Park, I. W. The clinical course of the idiopathic epiretinal membrane after surgery. Korean J. Ophthalmol. 23, 249–252 (2009).
Chan, J. C. N. et al. The lancet commission on diabetes: using data to transform diabetes care and patient lives. Lancet 396, 2019–2082 (2021).
Ng, D. S. C. et al. International consensuses and controversies on causes, diagnosis and management of diabetic macular edema (DME). Prog. Retin. Eye Res. 109, 101406. https://doi.org/10.1016/j.preteyeres.2025.101406 (2025).
Goebel, W. & Kretzchmar-Gross, T. Retinal thickness in diabetic retinopathy: A study using optical coherence tomography (OCT). Retina 22, 759–767 (2002).
Maheshwary, A. S. et al. The association between percent disruption of the photoreceptor inner segment-outer segment junction and visual acuity in diabetic macular edema. Am. J. Ophthalmol. 150, 63–67 (2010).
Vujosevic, S. et al. Diabetic macular edema with neuroretinal detachment: Oct and OCT-angiography biomarkers of treatment response to anti-VEGF and steroids. Acta Diabetol. 57, 287–296 (2020).
Tang, J. & Kern, T. S. Inflammation in diabetic retinopathy. Prog. Retin. Eye Res. 30, 343–358 (2011).
Sharma, S. & Mruthyunjaya, P. Corticosteroids for the treatment of diabetic macular edema. Curr. Ophthalmol. Rep. 2, 158–166 (2014).
McGuire, P. G. et al. Pericyte-derived sphingosine 1-phosphate induces the expression of adhesion proteins and modulates the retinal endothelial cell barrier. Arterioscler. Thromb. Vasc. Biol. 31, e107–e115 (2011).
Vujosevic, S. et al. Diabetic macular edema with and without subfoveal neuroretinal detachment: Two different morphologic and functional entities. Am. J. Ophthalmol. 181, 149–155 (2017).
Liu, Q. et al. Comparison of intravitreal triamcinolone acetonide versus intravitreal bevacizumab as the primary treatment of clinically significant macular edema. Retina 35, 272–279 (2015).
Mao, J. et al. Prediction of anti-VEGF efficacy in diabetic macular oedema using intraocular cytokines and macular optical coherence tomography. Acta Ophthalmol. 100, e891–e898 (2021).
Gardner, T. W. et al. Diabetic retinopathy: more than meets the eye. Surv. Ophthalmol. 48, S253–S262 (2003).
Titchenell, P. M. & Antonetti, D. A. Using the past to inform the future: Anti-VEGF therapy as a road map to develop novel therapies for diabetic retinopathy. Diabetes 62, 1808–1815 (2013).
Chan, G. C. Y. et al. Fusing results of several deep learning architectures for automatic classification of normal and diabetic macular edema in optical coherence tomography. Annu Int Conf IEEE Eng Med Biol Soc, 2018, 670–673. (2018).
Semeraro, F. et al. Diabetic retinopathy, a vascular and inflammatory disease: Therapeutic implications. Diabetes Metab. 45, 517–527 (2019).
Vujosevic, S. et al. Role of inflammation in diabetic macular edema and neovascular age-related macular degeneration. Surv. Ophthalmol. 69, 870–881 (2024).
Mello Filho, P. et al. Effectiveness and safety of intravitreal dexamethasone implant (Ozurdex) in patients with diabetic macular edema: A real-world experience. Ophthalmologica 241, 9–16 (2018).
da Silva, M. O. et al. Early choroidal and retinal changes detected by swept-source oct in type 2 diabetes and their association with diabetic kidney disease: A longitudinal prospective study. BMC Ophthalmol. 24, 85 (2024).
Farias, L. B. et al. Microalbuminuria is associated with early retinal neurodegeneration in patients with type 2 diabetes. Ophthalmic Surg. Lasers Imaging Retina 49, e36–e43 (2018).
Maheshwary, A. S. et al. The association between percent disruption of the photoreceptor inner segment-outer segment junction and visual acuity in diabetic macular edema. Am. J. Ophthalmol. 150, 63-67.e1 (2010).
Oster, S. F. et al. Disruption of the photoreceptor inner segment/outer segment layer on spectral domain-optical coherence tomography is a predictor of poor visual acuity in patients with epiretinal membranes. Retina 30, 713–718 (2009).
Yohannan, J. et al. Association of retinal sensitivity to integrity of photoreceptor inner/outer segment junction in patients with diabetic macular edema. Ophthalmology 120, 1–8 (2013).
Chatziralli, I. et al. Dexamethasone intravitreal implant in diabetic macular edema: Real-life data from a prospective study and predictive factors for visual outcome. Diabetes Ther. 8, 1393–1404 (2017).
Aydoğan Gezginaslan, T. et al. Does completion time of the initiation phase of anti-vascular growth factor affect visual and anatomical outcomes?: The marmasia study group report no.5. Eye (Lond). 39, 2579–2583 (2025).
Acknowledgements
Foundations: The work was supported by youth Science and technology Project of Hebei Provincial Health Commission (Project number: 20221423);the China Health Promotion Foundation(IIT-2025072).We also wish to acknowledge the valuable assistance provided by the medical writers, proofreaders and editors who contributed to the preparation of this manuscript.
Funding
The work was supported by youth Science and technology Project of Hebei Provincial Health Commission (Project number: 20221423);the China Health Promotion Foundation(IIT-2025072).
Author information
Authors and Affiliations
Contributions
Xiao-Nan Shi, Qian-ying Zhang, Chao-juan Ju and Yin-cong Xu made substantial contributions to the conception and design of the work, acquisition, analysis, and interpretation of data, and drafting of the manuscript. Zhao-hui Xiong made substantial contributions to the conception and design of the work, interpretation of data, and substantive revision of the manuscript for important intellectual content, and is responsible for the final approval of the version to be published.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Shi, Xn., Zhang, Qy., Ju, Cj. et al. Efficacy of Anti-VEGF therapy for different OCT Patterns in diabetic macular edema and the correlation between ellipsoid zone integrity and visual acuity. Sci Rep (2026). https://doi.org/10.1038/s41598-026-47416-7
Received:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41598-026-47416-7
